Radius Stock Rides Rollercoaster After ASBMR Bone Data
This article was originally published in Scrip
Executive Summary
Radius Health Inc. continues to report positive results for its osteoporosis therapy abaloparatide, but the company's stock has been on a somewhat bumpy ride since results were presented at the recent American Society of Bone and Mineral Research (ASBMR) meeting.